�the kind of review being proposed does not, at least initially, appear to bring anything new or needed to is already a robust system of oversight,� mogulof said in the statement. .-related side effects. its manufacturer, eli lilly, plans to submit a new drug application to the fda in the second half of 2018. .
OFF DEAL
218 Used Today
OFF DEAL
200 Used Today